Expertise in
17
conditions

Xiaodong M. Sun

NO. 1380, West Zhongshan Road, 
Zhongshan, CN 
Expertise in
17
conditions
NO. 1380, West Zhongshan Road, 
Zhongshan, CN 
OverviewLocationsClinical Research

Overview

Xiaodong Sun practices in Zhongshan, China. Sun is highly rated in 17 conditions, according to our data. Their top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Detachment, Vitrectomy, and Cataract Removal.

Their clinical research consists of co-authoring 424 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

NO. 1380, West Zhongshan Road, Zhongshan, 200336, China
Other Locations
100 Haining Road, Shanghai, 200080, China
99 Shangda Road, Shanghai, 200444, China
No. 100 Haining Road, Shanghai, 200080, China
No. 100 Haining Road, Hongkou, China
No.100 Hai Ning Road, Shanghai, 200080, China
Building 1, No.100, Haining Road, Shanghai, 200080, China
Haining Road 100, Shanghai, 200080, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase IV, Randomized, Observer-blind, Placebo-controlled, Multi-center Study to Assess the Prophylactic Efficacy Against Herpes Zoster, Immunogenicity and Safety of Shingrix When Administered Intramuscularly on a 2-dose Schedule in Chinese Adults Aged 50 Years and Older
A Phase IV, Randomized, Observer-blind, Placebo-controlled, Multi-center Study to Assess the Prophylactic Efficacy Against Herpes Zoster, Immunogenicity and Safety of Shingrix When Administered Intramuscularly on a 2-dose Schedule in Chinese Adults Aged 50 Years and Older
Enrollment Status: Completed
Publish Date: January 20, 2025
Intervention Type: Biological, Drug
Study Drug: RZV Subunit Vaccine
Study Phase: Phase 4
A Multicenter Study Comparing Efficacy and Safety of Treat-and-Extend Regimen Versus Pro Re Nata Regimen of Conbercept in Neovascular Age-related Macular Degeneration
A Multicenter Study Comparing Efficacy and Safety of Treat-and-Extend Regimen Versus Pro Re Nata Regimen of Conbercept in Neovascular Age-related Macular Degeneration
Enrollment Status: Unknown
Publish Date: May 19, 2020
Intervention Type: Drug, Procedure
Study Drug: Conbercept
Study Phase: Phase 4
View 1 Less Clinical Trial

419 Total Publications

Corrigendum to "Generation of the induced pluripotent stem cell line SJTUGHi004-A derived from a Best's disease patient with c.763C > T mutation in BEST1 gene" [Stem Cell Res. 88 (2025) 103806].
Corrigendum to "Generation of the induced pluripotent stem cell line SJTUGHi004-A derived from a Best's disease patient with c.763C > T mutation in BEST1 gene" [Stem Cell Res. 88 (2025) 103806].
Journal: Stem cell research
Published: October 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sun's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile